Disclaimer: This information is provided for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional, taking into account the individual patient's condition and current best practices. This content reflects current medical understanding and may be subject to change as new evidence emerges.

---

Choledochal Cyst

Overview

• Definition: Choledochal cysts (CDCs) are rare, congenital or acquired dilations of the biliary tree, involving the extrahepatic and/or intrahepatic bile ducts. They are not true cysts as they communicate with the biliary system.
• Epidemiology:
  • Incidence: Estimated incidence ranges from 1 in 13,000 to 1 in 150,000 live births in Western populations. Much higher incidence in Asian populations, particularly Japan (1 in 1,000 live births).
  • Demographics: Predominantly affects females (female-to-male ratio of 3-4:1). Can be diagnosed at any age, from antenatal period to adulthood, but most often in childhood.
• Classification: The Todani classification system (1977) is the most widely accepted:
  • Type I (Most Common, 80-90%): Cystic or fusiform dilation of the extrahepatic bile duct.
    • Ia: Cystic dilation of the common bile duct (CBD).
    • Ib: Focal segmental dilation of the CBD.
    • Ic: Fusiform dilation of the CBD.
  • Type II: Diverticulum protruding from the CBD wall.
  • Type III (Choledochocele): Dilation of the intraduodenal portion of the CBD.
  • Type IV: Multiple cysts.
    • IVa: Multiple cysts involving both intrahepatic and extrahepatic bile ducts.
    • IVb: Multiple cysts involving only the extrahepatic bile ducts.
  • Type V (Caroli's Disease): Multiple intrahepatic cysts. May involve diffuse or segmental intrahepatic duct dilation.

Pathophysiology

• Mechanism: The most widely accepted theory is that CDCs result from an anomalous pancreaticobiliary junction (APBDJ), where the pancreatic duct joins the common bile duct outside the duodenal wall, more than 1 cm proximal to the sphincter of Oddi. This allows for reflux of pancreatic enzymes into the biliary tree, leading to:
  • Chronic inflammation and irritation of the bile duct wall.
  • Weakening and progressive dilation of the duct.
  • Increased intraductal pressure due to sphincter of Oddi dysfunction.
  • This reflux creates a common channel that functions as a "common bile acid-pancreatic juice reservoir," leading to chronic cholangitis, stone formation, and increased risk of malignancy.
• Risk Factors:
  • APBDJ: Present in 50-80% of patients with CDCs, particularly Types I and IV.
  • Female Sex: Higher incidence in females.
  • Genetic Predisposition: While not fully elucidated, racial predilection (e.g., East Asian) suggests potential genetic components.
  • Bile Duct Anomalies: Association with biliary atresia in some cases.
• Protective Factors: None directly prevent the formation of a congenital anomaly. However, early diagnosis and complete surgical excision are protective against developing serious complications like cholangitis, pancreatitis, and cholangiocarcinoma.

Clinical Presentation

Signs and Symptoms

Clinical presentation varies widely with age. The classic triad of abdominal pain, jaundice, and a palpable abdominal mass is seen in less than 20% of cases, primarily in children. - Cardinal Features: - Abdominal Pain: Most common symptom, often vague, recurrent, episodic, and right upper quadrant (RUQ) or epigastric. May mimic biliary colic. - Jaundice: Fluctuating or persistent, often cholestatic in nature. - Palpable Mass: Less common, firm, non-tender, cystic mass in the RUQ. More typical in infants/young children with large cysts. - Early Signs (Infants/Children): - Neonatal cholestasis (prolonged jaundice). - Acholoric stools and dark urine. - Recurrent episodes of fever, abdominal pain, and vomiting (due to cholangitis). - Failure to thrive. - Advanced Signs (Adolescents/Adults): - Symptoms of recurrent cholangitis (fever, chills, RUQ pain, jaundice). - Acute pancreatitis (due to reflux of bile into the pancreatic duct or stone obstruction). - Cholelithiasis or choledocholithiasis. - Signs of portal hypertension (ascites, splenomegaly, variceal bleeding) in Type V (Caroli's disease) with advanced liver fibrosis. - Weight loss, anorexia, malaise, and signs of malignancy (cholangiocarcinoma). - Atypical Presentations: - Asymptomatic: Often an incidental finding during imaging for other conditions or antenatal ultrasound. - Isolated recurrent pancreatitis without other biliary symptoms. - Biliary obstruction mimicking gallstones.

Physical Examination

• Inspection:
  • Jaundice (scleral icterus, yellowish skin).
  • Abdominal distension (if large cyst).
  • Signs of malnutrition or chronic illness in children.
• Palpation:
  • RUQ Tenderness: Common, especially during episodes of cholangitis or pancreatitis.
  • Palpable Mass: A smooth, cystic, non-tender mass in the RUQ or epigastrium (rarely felt in adults).
  • Hepatomegaly or splenomegaly (in advanced cases or Type V).
• Special Tests:
  • Murphy's Sign: May be positive if acute cholecystitis or cholangitis is present, but not specific for CDC.

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and duration of symptoms (pain, jaundice, fever).
  • Character, location, radiation, and severity of abdominal pain.
  • History of dark urine or pale stools.
  • Episodes of cholangitis (fever, chills, jaundice, pain).
  • History of pancreatitis.
  • Age at diagnosis (if previously known).
  • Family history of liver or biliary disorders.
  • Previous abdominal surgeries or imaging studies.
• Red Flags:
  • Acute onset of severe RUQ pain with high fever and chills (suggests acute cholangitis).
  • Rapidly worsening jaundice.
  • Signs of sepsis (hypotension, tachycardia, altered mental status).
  • Unexplained weight loss or anorexia in adults (suggests malignancy).

Laboratory Tests

• First-Line:
  • Liver Function Tests (LFTs):
    • Bilirubin: Elevated, especially direct (conjugated) bilirubin, indicating cholestasis.
    • Alkaline Phosphatase (ALP) and Gamma-Glutamyl Transferase (GGT): Markedly elevated due to cholestasis.
    • Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT): Mild to moderate elevation, especially during acute cholangitis or pancreatitis.
  • Amylase and Lipase: Elevated during episodes of acute pancreatitis.
  • Complete Blood Count (CBC): Leukocytosis with left shift if cholangitis or pancreatitis is present. Anemia may be present with chronic disease.
  • Coagulation Profile (PT/INR): Important to assess liver synthetic function and prior to any invasive procedure.
• Confirmatory:
  • Tumor Markers:
    • CA 19-9: May be elevated, especially in adults with CDCs, and significantly elevated in cases of associated cholangiocarcinoma. However, it is non-specific and can be elevated in benign biliary conditions (e.g., cholangitis). Not a screening tool.
  • Serum Amylase and Lipase: To confirm pancreatitis.
• Monitoring:
  • Serial LFTs, CBC, and amylase/lipase to monitor disease activity or response to treatment.
  • Post-operative monitoring of LFTs to ensure patent anastomosis.
  • Long-term monitoring of CA 19-9 in select high-risk patients post-excision for malignancy surveillance, though its utility is debated.

Imaging

Imaging is crucial for diagnosis, classification, and surgical planning. - Recommended: - Abdominal Ultrasound (US): Often the initial imaging modality due to its non-invasiveness, accessibility, and lack of radiation. Can visualize dilated ducts, identify the cyst, and detect stones. May miss APBDJ or intrahepatic involvement. - Magnetic Resonance Cholangiopancreatography (MRCP): The gold standard for non-invasive diagnosis. Provides detailed anatomical delineation of the entire biliary tree, including intrahepatic and extrahepatic ducts, and the pancreatic duct, allowing for precise classification of the cyst type and identification of APBDJ. Excellent for surgical planning. - Computed Tomography (CT) Scan: Useful for assessing the extent of the cyst, its relationship to surrounding structures, and detecting complications like inflammation, abscesses, or associated malignancy. Also valuable for surgical planning and staging if malignancy is suspected. - Advanced: - Endoscopic Retrograde Cholangiopancreatography (ERCP): While historically used for diagnosis, it is now primarily a therapeutic modality due to its invasiveness and the availability of MRCP. Can confirm the diagnosis, visualize the APBDJ, remove stones, or place stents for drainage if severe cholangitis is present. - Intraoperative Cholangiography (IOC): Performed during surgery to confirm the diagnosis, delineate the extent of the cyst, identify associated anomalies (e.g., APBDJ), detect stones, and ensure no distal obstruction after anastomosis. - Percutaneous Transhepatic Cholangiography (PTC): Rarely used diagnostically for CDCs, primarily for drainage in cases of severe obstructive cholangitis or for visualizing ducts that cannot be accessed by ERCP.

Management

Acute Management

Aimed at stabilizing the patient, especially during acute complications like cholangitis or pancreatitis. - Immediate (First-Hour Interventions): - NPO (Nil per os): To rest the bowel and pancreas. - Intravenous (IV) Fluids: Aggressive hydration, especially in pancreatitis or sepsis. - Analgesia: Pain control with opioids (e.g., hydromorphone, morphine). - Broad-Spectrum Antibiotics: Initiate promptly if cholangitis or sepsis is suspected (e.g., piperacillin-tazobactam, meropenem, or a combination of a third-generation cephalosporin and metronidazole). - Stabilization (Early Management Priorities): - Correction of electrolyte imbalances. - Monitoring of vital signs, urine output, and serial laboratory tests (CBC, LFTs, amylase/lipase, inflammatory markers). - Close observation for signs of worsening sepsis or organ dysfunction. - Emergency (Crisis Management): - Biliary Decompression: If severe cholangitis with obstruction: - ERCP with Sphincterotomy and Stent Placement: Preferred method for immediate drainage of the common bile duct in acute cholangitis with obstruction. - Percutaneous Transhepatic Biliary Drainage (PTBD): Alternative if ERCP is unsuccessful or contraindicated. - Surgical Decompression: Rarely needed for acute management unless other less invasive methods fail or rupture occurs.

Chronic Management

Primarily surgical, with medical management focused on symptom control and pre/post-operative care. - Pharmacological: - Ursodeoxycholic Acid (UDCA): May be used to improve bile flow and prevent stone formation in select cases (e.g., Caroli's disease with intrahepatic stones) but is not a primary treatment for the cyst itself. - Antibiotics: For recurrent episodes of cholangitis or as prophylaxis around procedures. - Non-pharmacological: - Nutritional Support: Important for patients with chronic cholestasis or recurrent cholangitis to prevent malnutrition. - Avoidance of Alcohol: Especially important if pancreatitis is a recurrent issue. - Monitoring: - Post-operative Surveillance: Regular follow-up appointments. - Imaging: Periodic ultrasound or MRCP to check for anastomotic strictures, recurrent stones, or new lesions. Frequency varies (e.g., yearly for 5 years, then less frequently). - Laboratory Tests: Periodic LFTs. - Tumor Markers (CA 19-9): Controversial, but may be followed in patients considered high risk for cholangiocarcinoma (e.g., those with Type IV cysts or long-standing disease).

Treatment Algorithms

The definitive treatment for most choledochal cysts is complete surgical excision due to the significant risk of malignancy (cholangiocarcinoma), even after symptoms resolve. - First-Line: - Complete Excision of the Extrahepatic Cyst with Roux-en-Y Hepaticojejunostomy: This is the standard surgical procedure for Todani Type I, II, and IVa/b cysts. - The entire dilated extrahepatic bile duct, including the intrapancreatic portion, is resected. - The gallbladder is also removed (cholecystectomy) as it is often involved in the inflammatory process or may contain stones. - Biliary enteric continuity is restored by creating a Roux-en-Y hepaticojejunostomy (anastomosis of the common hepatic duct to a loop of jejunum) to prevent reflux of intestinal contents into the biliary tree. - For Type II (diverticulum), simple excision of the diverticulum with primary closure of the CBD is performed. - Second-Line: - For Type III (Choledochocele): - Endoscopic Sphincterotomy: For small choledochoceles, endoscopic resection (transduodenal or endoscopic) may be considered, but surgical excision (duodenotomy with excision and choledochoduodenostomy or hepaticojejunostomy) is preferred, especially for larger ones, due to potential for recurrence and malignancy. - For Type V (Caroli's Disease): - Segmental Hepatectomy: If the disease is localized to one or two liver segments, surgical resection of the affected liver portion may be performed. - Liver Transplantation: For diffuse, severe Caroli's disease with recurrent cholangitis, portal hypertension, or progressive liver failure. - Management of Complications: - Anastomotic Strictures: May require endoscopic dilation and stenting or surgical revision. - Intrahepatic Stones: Endoscopic or percutaneous extraction, or surgical clearance. - Refractory Cases: - Recurrent Cholangitis Post-Excision: Investigate for anastomotic stricture or intrahepatic stones. May require repeat intervention (endoscopic, percutaneous, or surgical). - Cholangiocarcinoma Development: Management depends on resectability, often involving radical surgery (Whipple procedure for distal CBD, hilar resection for proximal), chemotherapy, and/or radiation.

Complications

• Common:
  • Cholangitis: Recurrent episodes due to stasis and infection within the cyst.
  • Cholelithiasis/Choledocholithiasis: Stone formation within the cyst or gallbladder.
  • Acute Pancreatitis: Due to reflux of bile/pancreatic juice or obstruction by stones.
• Serious:
  • Cholangiocarcinoma: The most significant long-term complication, occurring in 10-30% of adult patients, with an average latency of 10-20 years. The risk is high even after partial excision, emphasizing the need for complete resection.
  • Rupture of the Cyst: A rare but life-threatening complication leading to bile peritonitis.
  • Biliary Cirrhosis and Portal Hypertension: Especially in long-standing cases or Type V (Caroli's disease).
  • Liver Abscess: Due to severe, unresolved cholangitis.
  • Sepsis: From severe cholangitis.
• Long-term:
  • Anastomotic Stricture: Post-surgical complication leading to biliary obstruction and recurrent cholangitis.
  • Recurrent Cholangitis: Can occur even after successful surgery, often due to strictures or intrahepatic stones.
  • Malignancy: Ongoing risk of cholangiocarcinoma, even after seemingly complete excision, particularly in patients with residual intrahepatic duct dilation or long-standing inflammation.

Prognosis

• Factors:
  • Todani Type: Type I and IV cysts have the highest malignant potential. Type V (Caroli's) has risks of liver failure and cholangiocarcinoma. Type III has a lower but still present malignancy risk.
  • Age at Diagnosis: Earlier diagnosis and surgical intervention generally lead to better outcomes and lower malignancy risk. Adults often present with more advanced disease or complications.
  • Presence of APBDJ: Increases the risk of cholangitis and malignancy.
  • Completeness of Excision: Incomplete excision significantly increases the risk of recurrent symptoms and cholangiocarcinoma.
  • Development of Complications: Especially cholangiocarcinoma, which significantly worsens prognosis.
• Survival:
  • Excellent with early and complete surgical excision. Long-term survival rates approach 90-95% when managed appropriately before malignancy develops.
  • Survival significantly reduced once cholangiocarcinoma develops (5-year survival for resected cholangiocarcinoma is typically 20-40%, much lower for unresectable).
• Quality of Life: Generally good after successful surgery. Some patients may experience chronic digestive issues or occasional mild abdominal pain. Surveillance is required, which can impact QoL.

Prevention

• Primary: Not applicable as CDCs are congenital malformations.
• Secondary:
  • Antenatal Ultrasound Screening: Can detect CDCs prenatally, allowing for early planning of postnatal evaluation and intervention. This is becoming more common and often leads to earlier diagnosis before symptoms or complications arise.
  • High Index of Suspicion: In patients presenting with recurrent abdominal pain, unexplained jaundice, or pancreatitis, especially children or those from high-prevalence areas.
• Tertiary:
  • Complete Surgical Excision: The most crucial preventative measure against future complications, especially malignancy. This should be performed electively once the diagnosis is made and the patient is stable.
  • Regular Post-operative Surveillance: To detect and manage complications like strictures or recurrent stones early, and to monitor for any signs of malignancy.

Special Populations

• Pediatric:
  • Presentation: Often present with jaundice, acholic stools (in infants), or recurrent abdominal pain/cholangitis (in older children). The classic triad is more common.
  • Diagnosis: Often detected antenatally or in infancy. MRCP is the preferred imaging.
  • Management: Surgical excision is typically performed electively once the child is stable and well-nourished. Excellent outcomes.
• Geriatric:
  • Presentation: Less common, often diagnosed in adulthood, sometimes with complications like cholangitis, pancreatitis, or malignancy. Higher likelihood of being asymptomatic or presenting with vague symptoms.
  • Management: Surgical risk is higher due to comorbidities. Careful pre-operative assessment and optimization are crucial. Malignancy risk is higher due to longer duration of exposure.
• Pregnancy:
  • Diagnosis during Pregnancy: Rare. Management is complex. If asymptomatic, surgery is typically deferred until after delivery. If symptomatic (e.g., acute cholangitis, pancreatitis), conservative management (IV fluids, antibiotics) is attempted. Surgical intervention (if absolutely necessary) carries risks to both mother and fetus.
  • Post-Excision: Pregnancy after successful CDC excision generally has no specific concerns related to the prior surgery.
• Comorbidities:
  • Liver Disease: Patients with underlying liver disease (e.g., cirrhosis from long-standing cholestasis in Caroli's disease) require careful pre-operative assessment of liver function.
  • Coagulation Disorders: Correct coagulopathy before surgery.
  • Cardiovascular/Pulmonary Disease: Manage optimize these conditions pre-operatively as surgical excision can be a major procedure.

Clinical Pearls

• Diagnostic:
  • Always suspect CDC in children with recurrent abdominal pain, jaundice, or pancreatitis, especially if there is no clear cause like gallstones.
  • MRCP is the diagnostic gold standard; it's non-invasive and provides comprehensive anatomical detail crucial for surgical planning.
  • Elevated CA 19-9 in an adult with a CDC should raise suspicion for malignancy but is not definitive.
• Treatment:
  • Complete surgical excision is mandatory for most types of CDCs (Todani Type I, II, IV) due to the high risk of cholangiocarcinoma, even in asymptomatic patients.
  • The entire extrahepatic biliary tree, including the intrapancreatic portion of the CBD and gallbladder, should be resected.
  • Roux-en-Y hepaticojejunostomy is the preferred method of biliary reconstruction to prevent reflux.
• Pitfalls:
  • Misdiagnosis: CDCs can be mistaken for other causes of biliary obstruction (e.g., choledocholithiasis, benign strictures), leading to delayed or inappropriate management.
  • Incomplete Excision: Resection of only the cystic portion without removing the entire extrahepatic duct (especially the intrapancreatic segment) significantly increases the risk of recurrence and malignancy.
  • Inadequate Follow-up: Patients, especially adults, require long-term surveillance post-excision due to the persistent, albeit reduced, risk of cholangiocarcinoma, particularly in the intrahepatic ducts if not fully resected.

Recent Updates

• Guidelines: Current guidelines continue to emphasize complete surgical excision as the definitive treatment due to malignancy risk. There's increasing focus on early diagnosis, often through prenatal screening.
  • American College of Surgeons (ACS), American Pediatric Surgical Association (APSA), and Japanese Society of Biliary Surgery provide relevant clinical recommendations.
• Evidence:
  • Growing evidence supports the role of laparoscopic or robotic approaches for surgical excision and reconstruction, offering benefits like smaller incisions, reduced pain, and faster recovery, with comparable safety and efficacy to open surgery in experienced centers.
  • Further research into the precise genetic mechanisms underlying APBDJ and CDC formation.
  • Improved understanding of the long-term risk of cholangiocarcinoma, leading to more tailored surveillance strategies.
• Controversies:
  • Optimal management of Type III (choledochocele): While endoscopic approaches are less invasive, the risk of malignancy may favor surgical excision for definitive treatment, especially for larger lesions.
  • Management of Type V (Caroli's disease): The decision between localized resection and liver transplantation remains complex, depending on the extent of disease, presence of complications, and liver function.
  • Utility of routine tumor marker surveillance (CA 19-9) post-excision: While often performed, its sensitivity and specificity for early recurrence or new malignancy remain debated.

Key References

• Guidelines:
  • Japanese Society of Biliary Surgery Guidelines: Often referenced due to high prevalence in Japan and extensive experience.
  • American Pediatric Surgical Association (APSA) Guidelines: For pediatric choledochal cyst management.
• Studies:
  • Todani T, et al. "Congenital bile duct cysts: classification, operative procedures, and review of 37 cases including 24 original cases." Am J Surg. 1977;134(2):263-9. (Original classification system)
  • Lipsett PA, et al. "Choledochal cyst disease. A ten-year surgical experience." Ann Surg. 1994;220(1):64-74.
  • Visser BC, et al. "Diagnosis and management of choledochal cysts in adults." J Am Coll Surg. 2004;199(1):97-106.
  • Singham J, et al. "Choledochal cysts: A 30-year single-centre experience." J Pediatr Surg. 2007;42(8):1360-4.
• Reviews:
  • Moslim MA, et al. "Choledochal cyst: An updated comprehensive review." World J Gastroenterol. 2016;22(44):9780-9791.
  • Soares KC, et al. "Choledochal cyst: Current management and new perspectives." World J Gastrointest Surg. 2017;9(1):1-10.